Vivos Therapeutics Updates Principal Office Address
Ticker: VVOS · Form: 8-K · Filed: Sep 18, 2025 · CIK: 1716166
| Field | Detail |
|---|---|
| Company | Vivos Therapeutics, Inc. (VVOS) |
| Form Type | 8-K |
| Filed Date | Sep 18, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, address-change
TL;DR
Vivos Therapeutics moved its main office to Littleton, CO.
AI Summary
Vivos Therapeutics, Inc. filed an 8-K on September 18, 2025, reporting an event on September 17, 2025. The filing indicates a change in the company's principal executive offices to 7921 Southpark Plaza, Suite 210, Littleton, Colorado 80120. The company's telephone number has also been updated to (720) 399-9322.
Why It Matters
This filing signals a physical relocation or administrative update for Vivos Therapeutics, Inc., which could impact operational logistics or investor relations contact information.
Risk Assessment
Risk Level: low — The filing reports a change of address, which is a routine administrative event with no immediate financial or operational risk.
Key Players & Entities
- Vivos Therapeutics, Inc. (company) — Registrant
- 7921 Southpark Plaza, Suite 210, Littleton, Colorado 80120 (location) — New Principal Executive Offices
- (720) 399-9322 (phone_number) — Updated Business Phone Number
FAQ
What is the new address for Vivos Therapeutics, Inc.'s principal executive offices?
The new address for Vivos Therapeutics, Inc.'s principal executive offices is 7921 Southpark Plaza, Suite 210, Littleton, Colorado 80120.
When was the change of address reported?
The change of address was reported on September 18, 2025, with the earliest event date being September 17, 2025.
What is the updated telephone number for Vivos Therapeutics, Inc.?
The updated telephone number for Vivos Therapeutics, Inc. is (720) 399-9322.
In which state is Vivos Therapeutics, Inc. incorporated?
Vivos Therapeutics, Inc. is incorporated in Delaware.
What was the former name of Vivos Therapeutics, Inc.?
The former name of Vivos Therapeutics, Inc. was Vivos BioTechnologies, Inc., with a name change date of September 1, 2017.
Filing Stats: 442 words · 2 min read · ~1 pages · Grade level 10.8 · Accepted 2025-09-17 20:41:12
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share VVOS The NASDAQ Stock Mar
Filing Documents
- form8-k.htm (8-K) — 36KB
- ex99-1.htm (EX-99.1) — 28KB
- 0001493152-25-013953.txt ( ) — 233KB
- vvos-20250917.xsd (EX-101.SCH) — 3KB
- vvos-20250917_lab.xml (EX-101.LAB) — 33KB
- vvos-20250917_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2025 Vivos Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39796 81-3224056 (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.) 7921 Southpark Plaza , Suite 210 Littleton , Colorado 80120 (Address of principal executive offices) (Zip Code) (720) 399-9322 (Registrant's telephone number, including area code) N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share VVOS The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 8.01 Other Information On September 17, 2025, Vivos Therapeutics, Inc. (the " Company ") issued a press release to announce first-time peer-reviewed data that confirms Vivos DNA (Daytime-Nighttime Appliance) is both safe and efficacious in treating children suffering from obstructive sleep apnea. A copy of such press release is filed as Exhibit 99.1 to this Current Report on Form 8-K. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated September 17, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VIVOS THERAPEUTICS, INC. Dated: September 17, 2025 By: /s/ Bradford Amman Name: Bradford Amman Title: Chief Financial Officer